Compare Figs Inc (FIGS) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs Viatris Inc — how do they compare? Figs Inc trades at $10 (market cap $1.66B), while Viatris Inc trades at $17.22 (market cap $19.44B). The key difference: Viatris Inc is far larger — about 11.7× Figs Inc's market cap, and Viatris Inc pays a 2.88% dividend while Figs Inc pays none. Which is the better fit depends on your goals.
| FIGS | VTRS | |
|---|---|---|
Market Cap | $1.66B | $19.44B |
Sector | Consumer Cyclical | Health |
52-Week High | $17.12 | $17.39 |
52-Week Low | $5.81 | $8.74 |
Enterprise Value | $1.44B | $31.65B |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS trades at $10.08, up 3.7% today, with a bearish technical signal despite recent earnings beats. Revenue grew to $631.1M in 2025 (Zacks Investment Research, 2026-05-07), but net cash flow remains negative. Analyst consensus is Buy with a $19.50 target, though technical indicators show selling pressure.
Outlook hinges on global expansion and margin management amid cost pressures. Risks include competitive threats and volatile cash flows, but strong customer growth and premium positioning offer upside if execution improves.
Viatris (VTRS) trades at $17.215, up 5.55% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3 billion in 2025 but posted a net loss of $3.51 billion, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a decision expected by December 2026. Analyst consensus leans toward Hold, with a $20 price target suggesting modest upside from current levels.
The outlook for VTRS hinges on successful pipeline execution and debt management, offering value potential if biosimilar and specialty drug launches gain traction. Key risks include persistent negative margins, high debt levels, and competitive pressures in the generics market. Investors should weigh the company's cost-cutting efforts and product diversification against its profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
